H.C. Wainwright Reiterates Buy Rating on Anavex Life Sciences (AVXL)

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $42.00 price target on Anavex Life Sciences (NASDAQ: AVXL).

The analyst commented: "In a press release and conference call last week, Anavex Life Sciences reported its F1Q25 financial results. The company finished the period ending December 31, 2024, with $120.8M in cash and cash equivalents, which it expects to be sufficient to fund operations at the current cash utilization rate for roughly four years. Anavex recorded a net loss of $0.14 per share, moderately narrower than our original forecast for a net loss of $0.17 per share. We reiterate our Buy rating and 12-month price target of $42."

For an analyst ratings summary and ratings history on Anavex Life Sciences click here. For more ratings news on Anavex Life Sciences click here.

Shares of Anavex Life Sciences closed at $8.52 yesterday.

You May Also Be Interested In

• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Packaging Corp. of America (PKG) PT Raised to $292 at UBS Following Containerboard Price Increase
• DA Davidson Reiterates Neutral Rating on Nebius Group (NBIS)